Published in Hepatitis Weekly, September 11th, 2000
Zonagen has been awarded a Phase I Small Business Innovation Research Grant (SBIR) from the U.S. National Institutes of Health (NIH) to conduct studies using Omniferon in targeting genital herpes. Omniferon is produced in Edinburgh, Scotland, and is currently in Phase II clinical trials in Europe for hepatitis C.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.